H.R. 4981, Opioid Use Disorder Treatment Expansion and Modernization Act

This estimate supersedes the cost estimate that CBO transmitted for H.R. 4981 on May 31, 2016. That earlier estimate did not account for the reduction in health care spending, the additional costs from reduced mortality rates for those people who comply with buprenorphine MAT, or for the effects of the bill on the costs of private health insurance coverage.